Abstract: The invention relates to systems and methods for the diagnosis, amelioration, and treatment of ischemic tissues in patients caused by and/or resulting from diminished microvascular blood flow. Patients suffering from ischemic tissue conditions can be categorized into specific subsets that are deemed to have a potential to respond to therapy. In particular, the invention includes various therapies involving stimulation of angiogenesis, vasculogenesis, arteriogenesis and/or neovascularization so as to increase perfusion of various tissues.

Abstract: The invention relates to systems and methods for the diagnosis, amelioration, and treatment of ischemic tissues in patients caused by and/or resulting from diminished microvascular blood flow. Patients suffering from ischemic tissue conditions can be categorized into specific subsets that are deemed to have a potential to respond to therapy. In particular, the invention includes various therapies involving stimulation of angiogenesis, vasculogenesis, arteriogenesis and/or neovascularization so as to increase perfusion of various tissues.

Abstract: Methods for the diagnosis and treatment of ischemic spinal conditions, degenerative disc disease, back pain and/or other tissue pathologies. Patients with ischemic spine disease can be categorized into subsets that are deemed to have potential to respond to therapy. In particular, therapies are disclosed which involve stimulation of neovascularization so as to increase perfusion of spinal and other anatomies.

Abstract: The invention relates to systems and methods for the diagnosis, amelioration, and treatment of ischemic tissues in patients caused by and/or resulting from diminished microvascular blood flow. Patients suffering from ischemic tissue conditions can be categorized into specific subsets that are deemed to have a potential to respond to therapy. In particular, the invention includes various therapies involving stimulation of angiogenesis, vasculogenesis, arteriogenesis and/or neovascularization so as to increase perfusion of various tissues.

Abstract: The invention relates to systems and methods for the diagnosis, amelioration, and treatment of ischemic tissues in patients caused by and/or resulting from diminished microvascular blood flow. Patients suffering from ischemic tissue conditions can be categorized into specific subsets that are deemed to have a potential to respond to therapy. In particular, the invention includes various therapies involving stimulation of angiogenesis, vasculogenesis, arteriogenesis and/or neovascularization so as to increase perfusion of various tissues.

Abstract: The invention relates to systems and methods for the diagnosis, amelioration, and treatment of ischemic tissues in patients caused by and/or resulting from diminished microvascular blood flow. Patients suffering from ischemic tissue conditions can be categorized into specific subsets that are deemed to have a potential to respond to therapy. In particular, the invention includes various therapies involving stimulation of angiogenesis, vasculogenesis, arteriogenesis and/or neovascularization so as to increase perfusion of various tissues.

Abstract: The invention relates to methods for the diagnosis, amelioration, and treatment of back pain, particularly lumbar back pain, in particular, back pain caused by muscular abnormalities, vertebral body osteoporosis, and disc degeneration. Patients with back pain are categorized into specific subsets that are deemed to have potential to respond to therapy. In particular, the invention includes a therapy involving stimulation of neovascularization so as to increase perfusion of various spine compartments.

Abstract: Methods for the diagnosis and treatment of ischemic spinal conditions, degenerative disc disease, back pain and/or other tissue pathologies. Patients with ischemic spine disease can be categorized into subsets that are deemed to have potential to respond to therapy. In particular, therapies are disclosed which involve stimulation of neovascularization so as to increase perfusion of spinal and other anatomies.

Abstract: Disclosed herein is a method of making integrated circuits. In one embodiment the method includes forming tungsten plugs in the integrated circuit and forming electrically conductive interconnect lines in the integrated circuit after formation of the tungsten plugs. At least one tungsten plug is electrically connected to at least one electrically conductive interconnect line. Thereafter at least one electrically conductive interconnect line is exposed to ionized air.

Abstract: The invention relates to methods for the diagnosis, amelioration, and treatment of back pain, particularly lumbar back pain, in particular, back pain caused by muscular abnormalities, vertebral body osteoporosis, and disc degeneration. Patients with back pain are categorized into specific subsets that are deemed to have potential to respond to therapy. In particular, the invention includes a therapy involving stimulation of neovascularization so as to increase perfusion of various spine compartments.

Abstract: Disclosed herein is a method of making integrated circuits. In one embodiment the method includes forming tungsten plugs in the integrated circuit and forming electrically conductive interconnect lines in the integrated circuit after formation of the tungsten plugs. At least one tungsten plug is electrically connected to at least one electrically conductive interconnect line. Thereafter at least one electrically conductive interconnect line is contacted with water for a period of time less than 120 minutes.

Abstract: Disclosed herein is a method of making integrated circuits. In one embodiment the method includes forming tungsten plugs in the integrated circuit and forming electrically conductive interconnect lines in the integrated circuit after formation of the tungsten plugs. At least one tungsten plug is electrically connected to at least one electrically conductive interconnect line. Thereafter at least one electrically conductive interconnect line is exposed to ionized air.

Abstract: Disclosed herein is a method of making integrated circuits. In one embodiment the method includes forming tungsten plugs in a integrated circuit and forming electrically conductive interconnect lines after formation of the tungsten plugs, wherein at least one tungsten plug is electrically connected to at least one electrically conductive interconnect line. Separate from the formation of the tungsten plugs and electrically conductive interconnect lines, a gas is introduced into a liquid. At least one electrically conductive interconnect line is then contacted with the gas introduced liquid.

Abstract: Disclosed herein is a method of making integrated circuits. In one embodiment the method includes forming tungsten plugs in the integrated circuit and forming electrically conductive interconnect lines in the integrated circuit after formation of the tungsten plugs. At least one tungsten plug is electrically connected to at least one electrically conductive interconnect line. Thereafter at least one electrically conductive interconnect line is contacted with water for a period of time less than 120 minutes.

Abstract: A method for inducing cell death in neoplastic cells, includes the step of administering a compound of formula I or a pharmaceutically acceptable salt thereof, as a primary chemotherapeutic agent or substantially contemporaneously with chemotherapy, to a patient having multidrug-resistant neoplastic cells, in an amount sufficient to induce cell death in the neoplastic cells: ##STR1## where R.sup.1 is hydroxyl, C1-4 alkoxyl, C1-4 alkylcarboxyloxymethoxyl, phenyl C1-2 alkylamino group, 2,5-pyrrolidinedione-1-alkoxyl (C1-4), or ##STR2## wherein X.sup.1 is a chemical bond or C1-2 alkylene, X.sup.2 is hydrogen or carboxyl forming a 5-membered ring with X.sup.1 when X.sup.1 is methylene, X.sup.3 is hydrogen or C1-2 alkyl, X.sup.4 is hydrogen or C1-2 alkyl, or X.sup.3 and X.sup.4 together form a 5-membered ring, in which at least one of X.sup.2, X.sup.3, and X.sup.4 is hydrogen,R.sup.2 is C3-4 alkyl, R.sup.3 is C1-4 alkyl, ##STR3## in which n is an integer of 0 to 3.

Abstract: A method for inducing cell death in neoplastic cells, includes the step of administering a compound of formula I or a pharmaceutically acceptable salt thereof, as a primary chemotherapeutic agent or substantially contemporaneously with chemotherapy, to a patient having multidrug-resistant neoplastic cells, in an amount sufficient to induce cell death in the neoplastic cells: ##STR1## where R.sup.1 is hydroxyl, C1-4 alkoxyl, C1-4 alkylcarboxyloxymethoxyl, phenyl C1-2 alkylamino group, 2,5-pyrrolidinedione-1-alkoxyl (C1-4), or ##STR2## wherein X.sup.1 is a chemical bond or C1-2 alkylene, X.sup.2 is hydrogen or carboxyl forming a 5-membered ring with X.sup.1 when X.sup.1 is methylene, X.sup.3 is hydrogen or C1-2 alkyl, X.sup.4 is hydrogen or C1-2 alkyl, or X.sup.3 and X.sup.4 together form a 5-membered ring, in which at least one of X.sup.2, X.sup.3, and X.sup.4 is hydrogen,R.sup.2 is C3-4 alkyl, R.sup.3 is C1-4 alkyl, ##STR3## in which n is an integer of 0 to 3.

Abstract: Purified plasminogen activator proteins obtained or derived from the vampire bat Desmodus rotundus saliva and salivary glands, methods for purifying the proteins, DNA sequences encoding these proteins, means for producing them using recombinant DNA technology, pharmaceutical compositions comprising these proteins and methods of treatment utilizing these proteins are provided.

Abstract: A method for inducing cell death in neoplastic cells, includes the step of administering a compound of formula I or a pharmaceutically acceptable salt thereof, as a primary chemotherapeutic agent or substantially contemporaneously with chemotherapy, to a patient having multidrug-resistant neoplastic cells, in an amount sufficient to induce cell death in the neoplastic cells: ##STR1## where R.sup.1 is hydroxyl, C1-4 alkoxyl, C1-4 alkylcarboxyloxymethoxyl, phenyl C1-2 alkylamino group, 2,5-pyrrolidinedione-1-alkoxyl (C1-4), or ##STR2## wherein X.sup.1 is a chemical bond or C1-2 alkylene, X.sup.2 is hydrogen or carboxyl forming a 5-membered ring with X.sup.1 when X.sup.2 is methylene, X.sup.3 is hydrogen or C1-2 alkyl, X.sup.4 is hydrogen or C1-2 alkyl, or X.sup.3 and X.sup.4 together form a 5-membered ring, in which at least one of X.sup.2, X.sup.3, and X.sup.4 is hydrogen,R.sup.2 is C3-4 alkyl, R.sup.3 is C1-4 alkyl, ##STR3## in which n is an integer of 0 to 3.

Abstract: A biochemically pure polypeptide(s), termed osteogenic growth polypeptide (OGP), which exhibits stimulatory effects on osteoblastic cells, in vivo bone formation and hemopoietic reconstruction. OGP, identified from regenerating bone marrow, has an amino acid sequence ofAla-Leu-Lys-Arg-Gln-Gly-Arg-Thr-Leu-Tyr-Gly-Phe-Gly-Gly.